[Indirect comparison methodology research for health technology assessment: Comparison of drug treatment effect in adult attention deficit hyperactivity disorder using a common comparator]

Ahn J, Jang BH, Choi M, An J, Shim J
Record ID 32014001093
Authors' recomendations: In this research, an indirect comparison methodology used in the context of Health Technology Assessment (HTA). As an example of HTA using indirect comparison, the efficacy of Atomoxetine and Methylphenidate in Adults Attention Deficit Hyperactivity Disorder(ADHD): A Rapid Review conducted by full term for NECA in 2012 was selected as an exemplar. Indirect comparison was performed using ITC program (version 1.0). The treatment effect of methylphenidate showed more significance in reducing ADHD symptoms compared to atomoxetine. The significant difference was readily evident when comparing OROS methylphenidate and atomoxetine. Such an effective difference has been proven through research involving children and adolescents (Hanwlla et al. 2011). Therefore, although there are not enough appropriate head-to-head trials for adult ADHD patients to compare the treatment effects of the two drugs, indirect comparison using a common comparator was effective to compare each treatment effect, and was proven by comparing the results to prior studies conducted with children and adolescents. There are numerous limitations to the use of indirect comparison for HTA, but it can be considered when head-to-head trials are absent. Furthermore, treatment effects resulting from indirect comparison can be used with direct comparison and different research methods to evaluate the significance of treatment effectiveness in clinical usage.
Project Status: Completed
Year Published: 2013
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: South Korea
MeSH Terms
  • Attention Deficit Disorder with Hyperactivity
  • Adrenergic Uptake Inhibitors
  • Methylphenidate
  • Meta-Analysis as Topic
Organisation Name: National Evidence-based healthcare Collaborating Agency
Contact Address: National Evidence-based Healthcare Collaborating Agency (NECA), 3~5F Health and Welfare Social Administration B/D, 400 Neungdong-ro, Gwangjin-gu, Seoul, Korea.
Contact Name: int@neca.re.kr
Contact Email: int@neca.re.kr
Copyright: National Evidence-based Healthcare Collaborating Agency (NECA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.